Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: mantle7 who wrote (1108)	6/3/1998 10:29:00 PM
From: Jeffrey L. Henken	Read Replies (2) \| Respond to of 2887

>Also, please explain just why AVE would be interested in ABMI's catheters? AVe's stent is already mounted on a catheter. Just where is AVE's product portfolio weak?< It is not. I just got off the phone with Dr Sam Ahn who told me that they have to use whatever catheter is available. There is not catheter bundled with AVE's stents yet. You also said World Medical had a proven product line. Not true all they sell in the US is catheters and they brought in $62 million for theit AAA stent system. To date AVEI is still a one trick pony. A very good pony but they could still use a broader portfolio. I have read post after post at the Yahoo AVEI thread that confirms that AVEI does not yet bundle their stents with a catheter. American BioMed's cathteters could be just the ticket. Will that happen? Probably not, I'll admit that but it's possible. What other products do they have that might round out AVEI's product line? How about the OmniCath? Arterial Vascular Engineering has no atherectomy device. Neither does JNJ. New protocols for the OmniCath are set for the phase II trials will be starting again. The markets that this atherectomy device will compete in are in excess of $500 million according to American Biomed's calculations. americanbiomed.com biz.yahoo.com biz.yahoo.com Perhaps the Guidewire MicroFilter(OmniFilter) which also will address a market as high as $500 million starting in early 1999. The Company has developed a percutaneous temporary filter which is mounted on a guide wire and is used to prevent stroke-causing blood clots from reaching various organs of the human body. americanbiomed.com americanbiomed.com American BioMed also has the OmniStent technology which could enter phase I testing this year. These stent designs are very similar to World Medicals. The bifurcated OmniStent™ is a Y-shaped bifurcated stent designed for use in aortic bifurcation. However, small versions may be used at any branched blood vessel: americanbiomed.com biz.yahoo.com American BioMed estimates that it's products compete in a $10 Billion market. Their silicone catheters no doubt have to compete more on the basis of price and performance than the fact they won't fragment if they fracture or cause an allergic reaction. Still they do have those added advantages. American BioMed will be present at the National Vascular Meeting in San Diego next week. So what kind of catheters is American BioMed currently shipping to distributors? You can check out some of these products and their competitive advantages: americanbiomed.com Latex Free, State-of-the-Art Silicone Balloon Catheters 100% silicone design; health care workers and patients avoid unnecessary risk of exposure to latex or PVC. Exclusive one-piece balloon catheter increases overall product smoothness reducing vascular trauma. Shatter-proof balloon. Syringe included with each catheter for easy and convenient preparation. Unique, integrated design eliminates use of a stylet. Smaller packaging increases ease of storage. Single Lumen Embolectomy Catheters Bi-Lumen Embolectomy and Irrigation Catheters Thermodilution Catheters Occlusion and Biliary Catheters Angiographic/Angioscopic Irrigation Catheters Foley (Urological) Catheters Drug Delivery Catheters Let's not forget the recently approved Ahn Thromectomy Catheter! This one could really be a big seller. AMERICAN BIOMED RECEIVES FDA APPROVAL TO MARKET NEW, SAFER THROMBECTOMY CATHETER americanbiomed.com All this great technology is the reason American BioMed was able to receive a $5 million equity line of credit which they will use as needed. biz.yahoo.com I would really appreciate your reading everything here with open mind. I'm not hyping this stock or this company. The technology is real. Latex allergies are real. The equity line of credit is real too. AVE or another company could benefit from an acquisition of American BioMed simply in terms of patent protection. Thanks for the homework assignment. Now I'm watching the second half of the game. Regards, Jeff